利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

49 条记录 (耗时 0.067 秒)

    SUBCONJUCTIVAL IMPLANT FOR POSTERIOR SEGMENT DRUG DELIVERY
    3.
    发明申请
    SUBCONJUCTIVAL IMPLANT FOR POSTERIOR SEGMENT DRUG DELIVERY 审中-公开
    用于分支部门药物递送的分支植入物

    公开(公告)号：US20130274692A1

    公开(公告)日：2013-10-17

    申请号：US13814470

    申请日：2011-08-04

    申请人： Yair Alster ,  Eugene De Juan, JR. ,  Kathleen Cogan Farinas ,  K. Angela MacFarlane ,  Cary J. Reich ,  Randolph E. Campbell ,  Signe Erickson

    发明人： Yair Alster ,  Eugene De Juan, JR. ,  Kathleen Cogan Farinas ,  K. Angela MacFarlane ,  Cary J. Reich ,  Randolph E. Campbell ,  Signe Erickson

    IPC分类号： A61F9/00

    CPC分类号： A61F9/0017 ,  A61K9/0051 ,  A61K31/00 ,  A61K31/573 ,  A61K31/58

    摘要： A therapeutic device can be configured to place the reservoir substantially between the conjunctiva and the scleral such that the size of the reservoir can be increased and the size of the scleral penetration decreased so as to decrease invasiveness. The device may comprise a substantially constant reservoir volume and drug release mechanism, in which the volume of the reservoir and mechanism are tuned to receive a quantity of therapeutic agent with a volume of injected formulation and release the therapeutic agent for an extended time with a release rate profile. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent, and a plurality of interconnecting channels can extend from the first side to the second side.

    摘要翻译： 治疗装置可以被配置为将储存器基本上放置在结膜和巩膜之间，使得储存器的尺寸可以增加并且巩膜穿透的尺寸减小以降低侵入性。 该装置可以包括基本上恒定的储存器体积和药物释放机构，其中储存器和机构的体积被调谐以接收一定量的具有注射制剂体积的治疗剂，并释放治疗剂延长的时间 费率简介。 多孔结构可以包括联接到储存器的第一侧和耦合到患者以释放治疗剂的第二侧，并且多个互连通道可以从第一侧延伸到第二侧。

    THERAPEUTIC AGENT FORMULATIONS FOR IMPLANTED DEVICES
    6.
    发明申请
    THERAPEUTIC AGENT FORMULATIONS FOR IMPLANTED DEVICES 审中-公开
    用于植入装置的治疗剂制剂

    公开(公告)号：US20140031769A1

    公开(公告)日：2014-01-30

    申请号：US13988298

    申请日：2011-11-18

    申请人： Eugene de Juan, JR. ,  Yair Alster ,  Steven M. Chamow ,  Kathleen Cogan Farinas ,  K. Angela MacFarlane ,  Cary J. Reich ,  Randolph E. Campbell ,  Signe Erickson ,  Blaine Bueche

    发明人： Eugene de Juan, JR. ,  Yair Alster ,  Steven M. Chamow ,  Kathleen Cogan Farinas ,  K. Angela MacFarlane ,  Cary J. Reich ,  Randolph E. Campbell ,  Signe Erickson ,  Blaine Bueche

    IPC分类号： A61F9/00

    CPC分类号： A61F9/0017 ,  A61K9/0051 ,  A61K9/1647 ,  A61K9/1652 ,  A61K31/573

    摘要： An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.

    摘要翻译： 治疗剂的可注射制剂可以包含治疗剂和稳定剂，使得当治疗剂从治疗装置释放时，大部分稳定剂保留在治疗装置中以稳定治疗剂。 可注射制剂可以包含一种或多种粘合剂颗粒或可侵蚀材料颗粒，使得可以将制剂注射到治疗装置中。 结合剂颗粒可以可逆地结合治疗剂以调节治疗剂的释放，并且可侵蚀的材料颗粒可以产生酸的质子，以增加治疗剂的稳定性并且可以调节治疗剂的释放。 治疗剂可以与稳定剂，结合剂颗粒或可侵蚀颗粒中的一种或多种组合以增加治疗剂的稳定性并且可以调节释放。

    Posterior Segment Drug Delivery
    9.
    发明申请
    Posterior Segment Drug Delivery 有权
    后期药物递送

    公开(公告)号：US20100255061A1

    公开(公告)日：2010-10-07

    申请号：US12696678

    申请日：2010-01-29

    申请人： Eugene de Juan, JR. ,  Yair Alster ,  Steven M. Chamow ,  Kathleen Cogan Farinas ,  Hanson S. Gifford, III ,  K. Angela MacFarlane ,  Cary J. Reich ,  Michael Barrett ,  Randolph E. Campbell ,  Robert George ,  Douglas Sutton

    发明人： Eugene de Juan, JR. ,  Yair Alster ,  Steven M. Chamow ,  Kathleen Cogan Farinas ,  Hanson S. Gifford, III ,  K. Angela MacFarlane ,  Cary J. Reich ,  Michael Barrett ,  Randolph E. Campbell ,  Robert George ,  Douglas Sutton

    IPC分类号： A61F9/00 ,  A61K39/395 ,  A61P27/02 ,  A61K31/5575 ,  A61K31/58 ,  A61F2/14 ,  B23P17/04

    CPC分类号： G01N33/558 ,  A61F9/0017 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/57 ,  A61K31/573 ,  A61K31/58 ,  A61K38/385 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/55 ,  Y10T29/49826

    摘要： A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. Each of the openings on the first side can be connected to each of the openings on the second side with the plurality of interconnecting channels, such that the rate of release of the therapeutic agent can be substantially maintained when one or more of the openings is blocked, for example with particles, cells, bacteria or tissue when the device is implanted for an extended time. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device many comprise an expandable retention structure and an expandable reservoir, such that the device can be delivered from a lumen of a delivery device and expand when positioned in the patient. The therapeutic device may comprises a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

    摘要翻译： 用于释放治疗剂的治疗装置包括联接到包括储存器的容器的多孔结构。 储存器包括体积大小，当耦合到多孔结构并且植入患者体内时，释放治疗剂量的治疗剂延长的时间。 所述多孔结构可以包括联接到所述储存器的第一侧和与所述患者联接以释放所述治疗剂的第二侧。 多个互连通道可以从第一侧延伸到第二侧，以便将第一侧上的第一多个开口与第二侧上的第二多个开口连接。 第一侧的每个开口可以与多个互连通道连接到第二侧的每个开口，使得当一个或多个开口被阻塞时可以基本上保持治疗剂的释放速度 ，例如当器件长时间植入时，可以使用颗粒，细胞，细菌或组织。 从第一侧延伸到第二侧的通道的长度可以包括大于多孔结构从第一侧到第二侧的距离的有效长度。 治疗装置许多包括可扩张的保留结构和可扩张的储存器，使得该装置可以从输送装置的内腔输送，并且在定位在患者体内时膨胀。 治疗装置可以包括当植入患者时将治疗剂注入装置中的可穿透屏障。

    IMPLANTABLE THERAPEUTIC DEVICE
    10.
    发明申请
    IMPLANTABLE THERAPEUTIC DEVICE 有权
    可植入治疗装置

    公开(公告)号：US20130324942A1

    公开(公告)日：2013-12-05

    申请号：US13814464

    申请日：2011-08-05

    申请人： Eugene de Juan, JR. ,  Yair Alster ,  Kathleen Cogan Farinas ,  K. Angela MacFarlane ,  Cary J. Reich ,  Randolph E. Campbell

    发明人： Eugene de Juan, JR. ,  Yair Alster ,  Kathleen Cogan Farinas ,  K. Angela MacFarlane ,  Cary J. Reich ,  Randolph E. Campbell

    IPC分类号： A61F9/00

    CPC分类号： A61F9/0017 ,  A61K9/0051

    摘要： A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the 188 second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

    摘要翻译： 用于释放治疗剂的治疗装置包括联接到包括储存器的容器的多孔结构。 储存器包括体积大小，当耦合到多孔结构并且植入患者体内时，释放治疗剂量的治疗剂延长的时间。 所述多孔结构可以包括联接到所述储存器的第一侧和与所述患者联接以释放所述治疗剂的第二侧。 从第一侧延伸到第二侧的通道的长度可以包括大于多孔结构从第一侧到第188侧的距离的有效长度。 治疗装置可以包括当植入患者时将治疗剂注射到装置中的可穿透屏障。